Quantification of femtomolar concentrations of the CYP3A substrate midazolam and its main metabolite 1′-hydroxymidazolam in human plasma using ultra performance liquid chromatography coupled to tandem mass spectrometry

Analytical and Bioanalytical Chemistry

Volumn 402, Issue 7, 2012, Pages 2439-2450

  Burhenne, Jürgen ^a   Halama, Birte ^a   Maurer, Monika ^a   Riedel, Klaus Dieter ^a   Hohmann, Nicolas ^a   Mikus, Gerd ^a   Haefeli, Walter E ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

1 hydroxymidazolam; CYP3A; Mass spectrometry; Midazolam; UHPLC

Indexed keywords

ANALYTES; CONCENTRATION RANGES; CORRELATION COEFFICIENT; CYP3A; CYTOCHROME P450; ELECTROSPRAY TANDEM MASS SPECTROMETRY; EXTRACTION RECOVERY; FEMTOMOLAR CONCENTRATION; HUMAN PLASMAS; HUMAN VOLUNTEERS; INTERNAL STANDARDS; ION SUPPRESSION; LOW DOSE; LOWER LIMITS; MIDAZOLAM; MULTIPLE-REACTION MONITORING MODES; PLASMA MATRIX; SAMPLE PREPARATION; SOLID-PHASE EXTRACTION; UHPLC; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ULTRASENSITIVE;

ACETONITRILE; DEUTERIUM; FORMIC ACID; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PLASMA (HUMAN);

ANESTHETICS;

CYTOCHROME P450 3A; MIDAZOLAM;

CALIBRATION; CONFERENCE PAPER; ENZYME SPECIFICITY; HUMAN; LIMIT OF DETECTION; LIQUID CHROMATOGRAPHY; METABOLISM; METHODOLOGY; QUALITY CONTROL; REPRODUCIBILITY; TANDEM MASS SPECTROMETRY; VALIDATION STUDY;

CALIBRATION; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 CYP3A; HUMANS; LIMIT OF DETECTION; MIDAZOLAM; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS; SUBSTRATE SPECIFICITY; TANDEM MASS SPECTROMETRY;

EID: 84859100891     PISSN: 16182642     EISSN: 16182650     Source Type: Journal    
DOI: 10.1007/s00216-011-5675-y     Document Type: Conference Paper

References (30)

1. FP Guengerich 2003 Cytochromes P450, drugs, and diseases Mol Interv 3 194 204 10.1124/mi.3.4.194 1:CAS:528:DC%2BD3sXmtFWitLs%3D
2. EL Michalets 1998 Update: clinically significant cytochrome P-450 drug interactions Pharmacotherapy 18 84 112 1:CAS:528:DyaK1cXpt1ylug%3D%3D
3. DD Breimer JH Schellens 1990 A "cocktail" strategy to assess in vivo oxidative drug metabolism in humans Trends Pharmacol Sci 11 223 225 10.1016/0165-6147(90)90245-4 1:CAS:528:DyaK3cXkslSms7o%3D
4. M Christensen K Andersson P Dalén RA Mirghani GJ Muirhead A Nordmark G Tybring A Wahlberg U Yaşar L Bertilsson 2003 The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes Clin Pharmacol Ther 73 517 528 10.1016/S0009-9236(03)00050-X 1:CAS:528:DC%2BD3sXkt1Ortbw%3D
5. H Zhou Z Tong JF McLeod 2004 "Cocktail" approaches and strategies in drug development: valuable tool or flawed science? J Clin Pharmacol 44 120 134 10.1177/0091270003261333 1:CAS:528:DC%2BD2cXhsVGjtLo%3D
6. S Chainuvati AN Nafziger JS Leeder A Gaedigk GL Kearns E Sellers Y Zhang ADM Kashuba E Rowland JS Bertino 2003 Combined phenotypic assessment of cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5∈+∈1 cocktail" Clin Pharmacol Ther 74 437 447 10.1016/S0009-9236(03)00229-7 1:CAS:528:DC%2BD3sXos1CjtbY%3D
7. Katzenmaier S, Markert C, Riedel K-D, Burhenne J, Haefeli WE, Mikus G (2011) Time course of CYP3A inhibition by potent reversible (voriconazole) and irreversible CYP3A inhibitors (ritonavir) using a limited sampling strategy. Clin Pharmacol Ther (in press)
8. SP Spina MH Ensom 2007 Clinical pharmacokinetic monitoring of midazolam in critically ill patients Pharmacotherapy 27 389 398 10.1592/phco.27.3.389 1:CAS:528:DC%2BD2sXjsVKks7c%3D
9. R Kaartama P Jarho J Savolainen H Kokki M Lehtonen 2011 Determination of midazolam and 1-hydroxymidazolam from plasma by gas chromatography coupled to methane negative chemical ionization mass spectrometry after sublingual administration of midazolam J Chromatogr B 879 1668 1676 10.1016/j.jchromb.2011. 04.009 1:CAS:528:DC%2BC3MXmtFCmsLY%3D
10. NB Tiscione X Shan I Alford DT Yeatman 2008 Quantitation of benzodiazepines in whole blood by electron impact-gas chromatography-mass spectrometry J Anal Toxicol 32 644 652 1:CAS:528:DC%2BD1cXht1aqs7zM
11. II Papoutsis SA Athanaselis PD Nikolaou CM Pistos CA Spiliopoulou CP Maravelias 2010 Development and validation of an EI-GC-MS method for the determination of benzodiazepine drugs and their metabolites in blood: applications in clinical and forensic toxicology J Pharm Biomed Anal 52 609 614 10.1016/j.jpba.2010.01.027 1:CAS:528:DC%2BC3cXjt1Kjt70%3D
12. KW Simonsen S Hermansson A Steentoft K Linnet 2010 A validated method for simultaneous screening and quantification of twenty-three benzodiazepines and metabolites plus zopiclone and zaleplone in whole blood by liquid-liquid extraction and ultra-performance liquid chromatography-tandem mass spectrometry J Anal Toxicol 34 332 341 1:CAS:528:DC%2BC3cXhtVCltLfM
13. J Gunn S Kriger AR Terrell 2010 Simultaneous determination and quantification of 12 benzodiazepines in serum or whole blood using UPLC/MS/MS Methods Mol Biol 603 107 119 10.1007/978-1-60761-459-3-10 1:CAS:528: DC%2BC3cXnt12ksL8%3D
14. SJ Marin R Coles M Merrell GA McMillin 2008 Quantitation of benzodiazepines in urine, serum, plasma, and meconium by LC-MS-MS J Anal Toxicol 32 491 498 1:CAS:528:DC%2BD1cXps1eks70%3D
15. S Turpault W Brian R van Horn A Santoni F Poitiers Y Donazzolo X Boulenc 2009 Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A Br J Clin Pharmacol 68 928 935 10.1111/j.1365-2125.2009.03548.x 1:CAS:528:DC%2BC3cXkvFOqtw%3D%3D
16. W Zhang F Han P Guo H Zhao ZJ Lin MQ Huang K Bertelsen N Weng 2010 Simultaneous determination of tolbutamide, omeprazole, midazolam and dextromethorphan in human plasma by LC-MS/MS-a high throughput approach to evaluate drug-drug interactions J Chromatogr B 878 1169 1177 10.1016/j.jchromb.2010.03.026 1:CAS:528:DC%2BC3cXlt1Cksbo%3D
17. Wohlfarth A, Naue J, Lutz-Bonengel S, Dresen S, Auwärter V (2011) Cocktail approach for in vivo phenotyping of 5 major CYP450 isoenzymes: development of an effective sampling, extraction, and analytical procedure and pilot study with comparative genotyping. J Clin Pharmacol (in press)
18. S Ghassabian M Chetty BN Tattam J Glen J Rahme Z Stankovic I Ramzan M Murray AJ McLachlan 2009 A high-throughput assay using liquid chromatography-tandem mass spectrometry for simultaneous in vivo phenotyping of 5 major cytochrome P450 enzymes in patients Ther Drug Monit 31 239 246 10.1097/FTD.0b013e318197e1bf 1:CAS:528:DC%2BD1MXjsFWqtr0%3D
19. K Ardjomand-Woelkart M Kollroser L Li H Derendorf V Butterweck R Bauer 2011 Development and validation of a LC-MS/MS method based on a new 96-well Hybrid-SPE-precipitation technique for quantification of CYP450 substrates/metabolites in rat plasma Anal Bioanal Chem 400 2371 2381 10.1007/s00216-010-4618-3 1:CAS:528:DC%2BC3MXkt1GgtQ%3D%3D
20. Svanström C, Hansson GP, Svensson LD, Sennbro CJ (2011) Development and validation of a method using supported liquid extraction for the simultaneous determination of midazolam and 1′-hydroxy-midazolam in human plasma by liquid chromatography with tandem mass spectrometry. J Pharm Biomed Anal (in press)
21. M Dostalek JS Macwan SD Chitnis IA Ionita F Akhlaghi 2010 Development and validation of a rapid and sensitive assay for simultaneous quantification of midazolam, 1′-hydroxymidazolam, and 4-hydroxymidazolam by liquid chromatography coupled to tandem mass spectrometry J Chromatogr B 878 1629 1633 10.1016/j.jchromb.2010.04.001 1:CAS:528:DC%2BC3cXmtFCjsL0%3D
22. H De Loor H De Jonge K Verbeke Y Vanrenterghem DR Kuypers 2010 A highly sensitive liquid chromatography tandem mass spectrometry method for simultaneous quantification of midazolam, 1′-hydroxymidazolam and 4-hydroxymidazolam in human plasma Biomed Chromatogr 25 1091 1098 10.1002/bmc.1576
23. US Department of Health and Human Services FDA (2001) Guidance for industry, bioanalytical method validation. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf. Accessed 13 Dec 2011
24. BK Matuszewski ML Constanzer CM Chavez-Eng 2003 Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS Anal Chem 75 3019 3030 10.1021/ac020361s 1:CAS:528: DC%2BD3sXltV2jsL8%3D
25. B Link M Haschke M Wenk S Krähenbühl 2007 Determination of midazolam and its hydroxyl metabolites in human plasma and oral fluid by liquid chromatography/electrospray ionization ion trap tandem mass spectrometry Rapid Commun Mass Spectrom 21 1531 1540 10.1002/rcm.2987 1:CAS:528: DC%2BD2sXltF2gu7k%3D
26. W Li S Luo HT Smith FLS Tse 2007 Simultaneous determination of midazolam and 1′-hydroxymidazolam in human plasma by liquid chromatography with tandem mass spectrometry Biomed Chromatogr 21 841 851 10.1002/bmc.829 1:CAS:528:DC%2BD2sXovVyjur4%3D
27. TM Annesley 2003 Ion suppression in mass spectrometry Clin Chem 49 1041 1044 10.1373/49.7.1041 1:CAS:528:DC%2BD3sXltFeisLg%3D
28. R Bonfiglio RC King TV Olah K Merkle 1999 The effects of sample preparation methods on the variability of the electrospray ionization response for model drug compounds Rapid Commun Mass Spectrom 13 1175 1185 10.1002/(SICI)1097-0231(19990630)13:12<1175::AID-RCM639>3.0.CO;2-0 1:CAS:528:DyaK1MXkt1ejtb8%3D
29. DJ Greenblatt DE Peters LE Oleson JS Harmatz MW MacNab N Berkowitz MA Zinny MH Court 2009 Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase Br J Clin Pharmacol 68 920 927 10.1111/j.1365-2125.2009.03545.x 1:CAS:528:DC%2BC3cXkvFOqtg%3D%3D
30. G Lappin W Kuhnz R Jochemsen J Kneer A Chaudhary B Oosterhuis WJ Drijfhout M Rowland RC Garner 2006 Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs Clin Pharmacol Ther 80 203 215 10.1016/j.clpt.2006.05.008 1:CAS:528:DC%2BD28XptFCgu7w%3D